<DOC>
	<DOCNO>NCT00154089</DOCNO>
	<brief_summary>The primary objective study determine pilot safety efficacy data topical formulation EM-1421 apply cervix patient CIN 1 , 2 , 3 .</brief_summary>
	<brief_title>A Pilot Study EM-1421 Treatment Cervical Intraepithelial Neoplasia</brief_title>
	<detailed_description>This open-label , pilot Phase I/II dose evaluation pharmacokinetic evaluation study compare safety efficacy terameprocol ( 45mg 90mg/application ) administer per week 3 week cervix uteri patient biopsy-proven CIN . Patients meet eligibility criterion visit clinic weekly terameprocol application . Patients keep daily diary card record genitourinary symptom .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Masoprocol</mesh_term>
	<criteria>18 year age older Negative pregnancy test Biopsy confirm CIN 1 , 2 , 3 Pregnancy breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>cervical intraepithelial neoplasia</keyword>
	<keyword>CIN</keyword>
	<keyword>HPV</keyword>
</DOC>